AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Epidermolysis Bullosa

Recent research efforts aimed at curing Epidermolysis Bullosa.

Last updated

Epidermolysis Bullosa

Overview

Epidermolysis Bullosa (EB) is a group of inherited disorders in which minor friction or trauma can cause skin—and sometimes the mouth, eyes, esophagus, and other mucosal surfaces—to blister or tear. The clinical severity varies widely among the major forms, including EB simplex, junctional EB, dystrophic EB, and Kindler EB; severe forms can cause chronic wounds, scarring, poor nutrition, infection, loss of mobility, and aggressive cutaneous squamous-cell carcinoma. Epidermolysis bullosa classification Dystrophic EB GeneReviews

Prognosis depends strongly on the causal gene and subtype. Some people have localized blistering and near-normal life expectancy, whereas severe recessive dystrophic EB (RDEB) and severe junctional EB can be life-limiting. Standard care remains multidisciplinary and largely supportive: protection from friction, non-adherent dressings, wound and infection management, pain and itch treatment, nutritional support, physiotherapy, dental and eye care, treatment of esophageal narrowing, and surveillance for skin cancer. Junctional EB GeneReviews American Academy of Dermatology: EB treatment

Scope of Recent Research (2020–present)

EB research has become notably more translational since 2020, especially for dystrophic EB caused by mutations in COL7A1, the gene for type VII collagen. The central questions are how to restore a durable supply of the missing structural protein, correct pathogenic variants safely, reach enough long-lived skin stem cells, and extend benefit beyond selected wounds to systemic complications. Two U.S.-approved gene-based therapies now improve RDEB/DEB wound healing, but neither is a whole-body, permanent cure for all EB types; durable genetic correction remains the field’s central unfinished goal. B-VEC phase 3 trial ZEVASKYN FDA review

Major Breakthroughs and Emerging Therapies

The leading breakthrough is topical gene replacement with beremagene geperpavec-svdt (B-VEC; VYJUVEK). This is a replication-deficient herpes-simplex-virus-1 vector that delivers a functional COL7A1 gene to DEB wounds so cells can make type VII collagen, the protein needed for anchoring fibrils that bind the outer and inner skin layers together. In the pivotal phase 3 trial, weekly B-VEC treatment produced complete healing at six months in 67% of treated wounds versus 22% of placebo-treated matched wounds; the U.S. Food and Drug Administration (FDA) approved it on May 19, 2023 for wounds in people with COL7A1-associated DEB. Because the vector does not integrate into the patient’s DNA and wounded skin continually turns over, it is a repeat-dose treatment rather than a permanent genetic repair. B-VEC phase 3 trial FDA approval of VYJUVEK

A second major advance is prademagene zamikeracel (ZEVASKYN; formerly EB-101), an autologous cell-based gene therapy. A patient’s keratinocytes are collected, expanded outside the body, given a functional COL7A1 copy using a retroviral vector, grown into epidermal sheets, and surgically applied to chronic RDEB wounds. In the phase 3 VIITAL trial, 81% of treated wounds achieved at least 50% healing by week 24, compared with 16% of matched standard-care control wounds, with greater pain reduction in treated wounds. The FDA approved ZEVASKYN on April 28, 2025 for RDEB wounds, establishing the first approved cell-based gene therapy for EB. VIITAL phase 3 trial ZEVASKYN FDA review

Gene editing seeks to repair the patient’s own gene rather than add an extra copy. In 2024, investigators reported CRISPR-Cas9 correction of a disease-causing COL7A1 variant in primary patient keratinocytes and fibroblasts, achieving up to 58% correction in treated cells and restoring type VII collagen in laboratory-grown skin grafts transplanted into mice. Other studies have tested exon deletion or “exon skipping” approaches, in which editing removes a mutation-containing exon while preserving enough of the protein to restore function. These results are important preclinical proofs of concept, but they have not yet established an approved human editing therapy. CRISPR homology-directed repair study CRISPR topical-delivery study

RNA-based approaches may offer a reversible alternative to DNA editing. RNA trans-splicing uses an engineered RNA molecule to replace a mutated portion of the COL7A1 messenger RNA before it is translated into protein; a 2022 study demonstrated replacement of exons 1–64 in patient-derived cells. This strategy could potentially address many mutations with fewer permanent genomic changes, but efficient, durable, and sufficiently targeted delivery remains a major barrier. COL7A1 RNA trans-splicing study

Regenerative medicine is also moving toward more complex replacement skin. A 2024 study developed a scalable, manufacturing-compatible platform that combined CRISPR correction with patient-derived induced pluripotent stem cells (iPSCs), then produced multi-cell-layer skin grafts containing epidermal, dermal, and pigment-cell components. Corrected grafts restored type VII collagen in mouse transplants, illustrating a potential future route to personalized, more complete skin replacement. CRISPR-corrected iPSC skin-graft platform

Clinical Trials and Experimental Approaches

The completed GEM-3 phase 3 study of B-VEC enrolled 31 people with dominant or recessive DEB and used an especially useful within-person design: matched wounds on the same participant received either B-VEC or placebo. The study’s positive wound-healing results supported FDA approval, while subsequent studies continue to examine repeat administration and use in additional settings. A 2024 case report also described ophthalmic B-VEC administration in a person with DEB-associated scarring conjunctivitis, with improved visual acuity after surgery; this was a single-patient report, not proof of broad ocular efficacy. GEM-3 ClinicalTrials.gov record Ocular B-VEC case report

The completed VIITAL phase 3 trial tested one-time surgical placement of ZEVASKYN sheets on large, chronic RDEB wounds at Stanford University and the University of Massachusetts Chan Medical School. Only 11 participants were enrolled, reflecting the rarity of RDEB, so long-term follow-up is particularly important. FDA required a prospective post-marketing observational study to characterize secondary-malignancy risk and long-term safety after ZEVASKYN treatment. VIITAL phase 3 trial ZEVASKYN FDA review

Methodologies and Scientific Approaches

Researchers combine patient-derived keratinocytes and fibroblasts with three-dimensional engineered skin, immunodeficient-mouse grafting, microscopy of the dermal–epidermal junction, and measurement of type VII collagen and anchoring fibrils. These systems allow teams to test whether a therapy merely produces protein in a dish or actually improves skin adhesion after transplantation. CRISPR homology-directed repair study B-VEC phase 3 trial

Delivery technology is a decisive research focus. Current platforms include topical non-integrating HSV-1 vectors, retrovirally modified autologous skin sheets, CRISPR ribonucleoprotein complexes, nonviral polymers, and iPSC-derived grafts. Researchers assess editing accuracy with targeted and whole-genome sequencing, investigate possible off-target alterations, and use collagen expression, wound closure, pain, and anchoring-fibril formation as practical biomarkers of correction. CRISPR topical-delivery study CRISPR-corrected iPSC skin-graft platform

Leading Institutions and Funding

Stanford University, the University of Massachusetts Chan Medical School, the University of Miami’s Bascom Palmer Eye Institute, the University of California–affiliated EB research community, and European centers including the Imagine Institute in Paris and EB House Austria are prominent academic contributors. Industry partners include Krystal Biotech, developer of B-VEC, and Abeona Therapeutics, developer of ZEVASKYN. VIITAL phase 3 trial Ocular B-VEC case report CRISPR homology-directed repair study

Patient-led organizations remain unusually important in this rare-disease field. EB Research Partnership funds projects intended to move toward commercially feasible EB therapies, while the EB Research Network offers grants of up to €90,000 per year for 12–36-month projects. LifeArc and DEBRA Austria also committed £2.5 million to a program focused on repurposed therapies, chronic inflammation, fibrosis, and cancer initiation in EB. EB Research Partnership grants EB Research Network grants LifeArc–DEBRA Austria program

Strengths, Limitations, and Challenges

The strongest evidence now supports local restoration of type VII collagen in DEB wounds. B-VEC is repeatable and avoids genomic integration, while ZEVASKYN can provide a one-time corrected epidermal sheet for selected difficult wounds. However, both approaches are localized: they do not repair every affected skin and mucosal surface, reverse established scarring, or correct the underlying mutation throughout the body. B-VEC phase 3 trial VIITAL phase 3 trial

For gene editing and iPSC approaches, major remaining issues include mutation-by-mutation personalization, delivering editors safely to enough long-lived stem cells, avoiding unwanted DNA changes, demonstrating long-term graft durability, and scaling costly individualized manufacturing. The small size of EB trials also limits certainty about rare adverse events; accordingly, ZEVASKYN has a required long-term post-marketing safety study. Access may be constrained by specialized wound care, surgery, cell-manufacturing capacity, and the need for experienced EB treatment centers. CRISPR homology-directed repair study ZEVASKYN FDA review

Outlook and Future Directions

As of October 15, 2026, EB is closer to meaningful genetic disease modification than at any prior point, particularly for COL7A1-related dystrophic EB, but a universal cure is not imminent. The next milestones are durable follow-up of B-VEC and ZEVASKYN-treated wounds, post-marketing safety data, demonstration that edited or iPSC-derived skin can persist without tumor formation, and therapies that safely correct broad areas of skin and internal mucosa. A genuine cure will likely require durable correction of self-renewing skin stem cells, scalable delivery, and solutions tailored to the many genes and EB subtypes—not only COL7A1-related disease. ZEVASKYN FDA review CRISPR-corrected iPSC skin-graft platform

References

Don't see your disease? Request a report